Biogen Inc (BIIB)

287.00 +1.50  +0.53% NASDAQ Jan 21, 16:58 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
04/24/2020 08:00 EDT Misc Biogen Inc First Quarter Earnings Conference Call in 2020
04/24/2020 Earnings Biogen Inc First Quarter Earnings in 2020 Release
01/30/2020 08:00 EST Misc Biogen Inc Fourth Quarter Earnings Conference Call for 2019
01/30/2020 Earnings Biogen Inc Fourth Quarter Earnings in 2019 Release
10/22/2019 08:00 EDT Misc Biogen Inc Third Quarter Earnings Conference Call for 2019
10/22/2019 Earnings Biogen Inc Third Quarter Earnings in 2019 Release
07/23/2019 08:00 EDT Misc Biogen Inc Second Quarter Earnings Conference Call in 2019
07/23/2019 Earnings Biogen Inc Second Quarter Earnings in 2019 Release
06/19/2019 09:00 EDT Misc Biogen Inc Annual General Meeting in 2018
04/24/2019 Earnings Biogen Inc First Quarter Earnings Results in 2019
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.biogen.com
  • Investor Relations URL: https://www.biogen.com/en_us/investors.html
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Jan. 30, 2020
  • Last Earnings Release: Oct. 22, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis.

Top Fund Holders

Symbol Name Weighting
LMPFX ClearBridge Aggressive Growth FI 8.43%
IBB iShares Nasdaq Biotechnology ETF 6.13%
VPMCX Vanguard PRIMECAP Inv 3.38%
FBT First Trust NYSE Arca Biotech ETF 3.33%
FBIOX Fidelity® Select Biotechnology 3.27%
VHCOX Vanguard Capital Opportunity Inv 2.94%
MOAT VanEck Vectors Morningstar Wide Moat ETF 2.53%
VPCCX Vanguard PRIMECAP Core Inv 1.73%
XBI SPDR® S&P Biotech ETF 1.66%
VGHCX Vanguard Health Care Inv 1.48%
XLV Health Care Select Sector SPDR® ETF 1.32%
VHT Vanguard Health Care ETF 1.22%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.